Year: 2025

Review of Accomplishment Rich 2025 Year with High Value Projections for 2026 as Cybersecurity Protection Becomes Increasingly Vital to Everyone MCLEAN, Va., Dec. 30, 2025 (GLOBE NEWSWIRE) — Cycurion, Inc. (NASDAQ: CYCU) (“Cycurion” or the “Company”), a leading AI driven, tech-enabled cybersecurity solutions provider, today releases the following Letter to Shareholders from Kevin Kelly, Chairman and Chief Executive Officer. Dear Cycurion Shareholders: As we close out this productive and successful year of 2025 with an impressive $80 million company contracted backlog orders on our books, we now look forward to significantly expanding our AI powered cybersecurity business plan for 2026 and beyond. At this moment, I would like to review for you some of our most significant milestones and reflect upon the Cycurion vision in the increasingly...

DAVENPORT, Iowa, Dec. 30, 2025 (GLOBE NEWSWIRE) — Lee Enterprises, Incorporated (the “Company” and Nasdaq: LEE) today announced that it has entered into a definitive stock purchase agreement for a $50 million strategic equity investment in the Company’s common stock. The investment is led by David Hoffmann (“Hoffmann”), with participation from other existing investors in the Company, providing the Company with committed capital and a strengthened financial and governance foundation as it moves into its next phase. Under the agreement, the Company has entered into a $50 million private placement of common stock at an investment price of $3.25 per share anchored and fully backstopped by Hoffmann, who initially committed a minimum of $20 million, with the remaining $30 million allocated to other top existing investors. As a result...

Company prepares for shipment of first EasyFEN™ system to Africa as part of global deployment strategy MANKATO, Minn., Dec. 30, 2025 (GLOBE NEWSWIRE) — Easy Environmental Solutions, Inc. (OTC: EZES) today announced the completed construction and availability of the EasyFEN Liquid Microbial Production System, with the first system to be shipped and deployed to East Africa. Subsequent units are in process for deployment into Central America, Europe, West Africa, and the United States.  The patent pending technology of the EasyFEN™ system will extract juices from local biomass and seed it with proprietary microbials to produce Terreplenish, a 100% organic soil amendment designed to restore soil health and enhance agricultural productivity. Each EasyFEN™system will process up to 17,500 tons of green biomass,...

PALI-2108 is the first and only PDE4 inhibitor in development targetingthe terminal ileum and colon for treatment of ulcerative colitis (UC) and fibrostenotic Crohn’s disease (FSCD) to address significant unmet medical needs Ongoing development of PALI-2108 across FSCD and UC, with Phase 2 IND submission planned for H1 2026 Carlsbad, CA, Dec. 30, 2025 (GLOBE NEWSWIRE) — Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage biopharmaceutical company developing next-generation, once-daily, oral PDE4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon, today announced that the Japan Patent Office (JPO) has granted a key patent covering PALI-2108, the Company’s lead, gut-microbiota-activated PDE4 B/D inhibitor being advanced for fibrostenotic Crohn’s disease (FSCD) and moderate...

Transaction anticipated to be highly accretive at an indicative 4X Proforma EBITDA with an implied valuation of ~$40 Million Exclusive heads of agreement in place for acquisition to be funded through a combination of deferred vendor finance and a convertible preference share tranche with $6.80 conversion price Acquisition expected to return VivoPower to group-level profitable status post-closing AI readiness of the site attributable to already energized hydropower with a very low cost at sub $0.035/kWh LONDON, UK / OSLO, NORWAY, Dec. 30, 2025 (GLOBE NEWSWIRE) — VivoPower International PLC (NASDAQ: VVPR) (“VivoPower” or the “Company”), a leading B Corp-certified global sustainable energy solutions group, is pleased to announce the execution of an exclusive heads of agreement to acquire an energized and operational 40MW+ data center...

TEL AVIV, Israel, Dec. 30, 2025 (GLOBE NEWSWIRE) — SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that NeuroThera Labs Inc. (TSXV: NTLX) (“NeuroThera”), a clinical-stage pharmaceutical company focused on developing novel treatments for central nervous system disorders, in which SciSparc holds a controlling interest of approximately 75%, announced that the Israel Patent Office has granted a patent for its proprietary combination of opioids and N-acylethanolamines. This patent covers methods and formulations designed to potentiate the therapeutic effects of opioids while significantly reducing associated side effects, such as tolerance, dependence, and gastrointestinal issues. This patent grant in Israel joins previously granted patents for the same technology in Europe, Japan, Australia, and...